In keeping with the Gentris mission to promote excellence in pharmacogenomics testing, Gentris members are actively engaged in pharmacogenomic research with academic partners.
Scott Clark, VP of Global Scientific Operations at Gentris, and colleagues from the University of North Carolina at Chapel Hill, North Carolina State University, University of Michigan, Lineberger Comprehensive Cancer Center and the Moffitt Cancer Center recently published their results which examined the association of genetic variants with peripheral neuropathy in breast cancer patients treated with paclitaxel.
Paclitaxel is commonly used to treat breast tumors. It is understood that levels of toxicity differ significantly among patients and is dependent on drug exposure and genetics. In addition, the risk of developing sensory peripheral neuropathy is elevated in African-American patients. Read the rest of this entry »
Date: September 8 – 10, 2014
Location: Raleigh, NC
Next Phase of Growth at Gentris Corporation to be Led by New Executive Team Including New Hires Dr. Heath Knight and Mr. Joseph Kessler
February 20, 2014
Morrisville, N.C. – Gentris Corporation (www.gentris.com), a global leader in pharmacogenomics solutions, biomarker testing and biorepository services, announced today the addition of Dr. Heath Knight as vice president, corporate development and Mr. Joseph Kessler, as chief operating officer. These two executives join the executive leadership team as the company anticipates its next phase of growth.
Creating “Holes” for a Lifetime- Refocusing the Culture at Gentris Corp and an Homage to It’s a Wonderful Life
Amelia Wall Warner, PharmD, RPh
CEO and President, Gentris Corporation
Date: November 5 – 6, 2013
Location: Cambridge, Massachusetts
Drug discovery is a long, costly process with a high attrition rate, and a personalized medicine strategy is needed to improve clinical outcomes. Identifying the subclass of patients who is likely to respond to drugs and developing biomarkers for patient stratification before recruitment for clinical trials would improve efficacy and response rates. Cambridge Healthtech Institute’s Inaugural Biomarkers for Patient Stratification meeting will explore the integration of biomarkers and companion diagnostics into drug development, case studies of using biomarkers to guide clinical decision making, molecular profiling approaches and their impact on clinical development, as well as personalized medicine initiatives at big pharma.
Date: November 4 – 5, 2013
Location: Indianapolis, Indiana
Today, biospecimen collections are used by multiple research groups for varying research aims, from basic research through clinical trials. A well-managed biobank is a critical prerequisite for high-quality biological research. The proper collection, processing, storage and tracking of biospecimens are critical components allowing researchers to better link molecular and clinical information. Thus, by necessity, biobanking is both a science and a business. Cambridge Healthtech Institute’s Fifth Annual Leaders in Biobanking: Maximizing Your Investment in Biospecimens addresses both the business and science of biobanking, bringing together biomedical and biopharmaceutical researchers, regulators, biorepository managers and practitioners to investigate the best strategies for effective use of biospecimens within today’s cutting-edge research.